Coronavirus Protein Microarray



Highly sensitive - Can detect 50pg antibodies which is 1000x lower than ELISA method.

Test ~30 COVID-19 positive serum with sensitivity rate 97% - higher than FDA request 90% 

Test ~30 control serum with specificity rate 97% - higher than FDA request 95%

Find a panel of biomarkers for rapid test - 2-3 biomarkers with same sensitivity and specificity


Experimental procedures for the serological antibodies

Quality control of the SARS-CoV-2 Microarray

Technical advances


Simultaneously detect serum IgG/IgM and profile the immune responses against many coronaviral proteins.



Since we compare many proteins from SARS-CoV-2, SARS-CoV, and MERS-CoV, the false negative or non-specific bindings can be evaluated. Also, the combination of multiple markers always can help the specificity and accuracy for the diagnosis.



We can include the protein with common mutations that observed in the clinical samples and provide a deeper view of the impact of SARS-CoV-2 mutations. For the clinical applications, it is also flexible to discover and combine different markers for the diagnosis, prognosis, and severity classifications.



Only need 1 microliter serum the assay which is less than a drop of blood. In a microliter, we can acquire numerous data information for the research, clinical, and epidemical uses.



The protein microarray is a useful platform to show the specificity of the biologicals. The coronavirus protein array will speed up the process of developing biologicals and help to evaluate the outcome of humoral immunity for the vaccines.



    客製化服務 產品 聯絡我們